notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title 1. 造血幹細胞移植後の移植片対宿主病の病態メカニズムとその制御
Subtitle 特集 肺移植 - 呼吸器医が知っておきたい我が国の現状 - 基礎医学とのダイアローグ
Authors 池川俊太郎, 松岡賢市
Authors (kana)
Organization 岡山大学病院血液・腫瘍内科, 岡山大学病院血液・腫瘍内科准教授
Journal THE LUNG perspectives
Volume 27
Number 4
Page 319-324
Year/Month 2019 /
Article 報告
Publisher メディカルレビュー社
Abstract 「Summary」同種造血幹細胞移植(hematopoietic stem cell transplantation:HSCT)は, 近年, 造血幹細胞ソースや移植法の多様化, また支持療法の向上を背景に, その適応を拡大し, 長期生存者が増加している. 一方で, 移植後半年を超えて発症する慢性移植片対宿主病(graft-versus-host disease:GVHD)やその関連疾患など晩期合併症が問題となっている. とりわけ, 移植後非感染性肺疾患は長期生存者の生命予後に影響する重要な合併症であり, 早期診断と治療法の確立は喫緊の課題となっている. 本稿ではまず一般的なHSCT後のGVHDについてまとめ, 次いで, 肺慢性GVHDである閉塞性細気管支炎について概説する.
Practice 臨床医学：内科系
Keywords 同種造血幹細胞移植, 移植片対宿主病, 閉塞性細気管支炎
  • 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
download全文ダウンロード(6.81MB)

参考文献

  • 1) MacDonald KP, Blazar BR, Hill GR. Cytokine mediators of chronic graft-versus-host discase, J Clin Invest. 2017;127(7):2452-63.
  • 2) Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation. Nat Rev Cancer. 2018;18(5):283-95.
    pubmed
  • 3) Zeiser R, Blazar BR. Acute Graft-versus-Host Disease-Biologic Process, Prevention, and Therapy. N Engl J Med. 2017;377(22):2167-79.
    pubmed
  • 4) Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Discase and Therapeutic Targets. N Engl J Med. 2017;377(26):2565-79.
  • 5) Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651-7.
    pubmed
残りの36件を表示する
  • 6) Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242-9.
  • 7) Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007;110(10):3804-13.
    pubmed
  • 8) Sarantopoulos S, Stevensen KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13(20):6107-14.
  • 9) Silnivasan M, Flynn R, Price A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570-80.
  • 10) Sakoda Y, Hashimoto D, Asakura S, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood. 2007;109(4):1756-64.
    pubmed
  • 11) Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120(5):1479-93.
    pubmed
  • 12) Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood. 2003;102(10):3822-8.
    pubmed
  • 13) Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med. 2014;370(19):1820-8.
  • 14) Ueda K, Watadani T, Maeda E, et al. Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. Bone Marrow Transplant. 2010;45(12):1719-27.
    pubmed
  • 15) Sakaida E, Nakaseko C, Harima A, et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood. 2003;102(12):4236-42.
    pubmed
  • 16) Dirou S, Malard F, Chambellan A, et al. Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for rcduced-inensity conditioning allogeneic SCT. Bone Marrow Transplant. 2014;49(5):622-7.
  • 17) Kuzmina Z, Krenn K, Petkov V, et al. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood. 2013;121(10):1886-95.
  • 18) Bergeron A. Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Chest Med.2017;38(2):249-62.
    pubmed
  • 19) Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis oblitcrans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S106-14.
  • 20) Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129(4):448-55.
  • 21) Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-56.
  • 22) Chellapandian D, Lehrnbecher T, Phillips B, et al. Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoictic stem-cell transplantation recipients: a systematic review and meta-analysis. J Clin Oncol. 2015;33(5):501-9.
  • 23) Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401 e381.
  • 24) Abbas S, Raybould JE, Sastry S, de la Cruz O. Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles. Int J Infect Dis. 2017;62:86-93.
    pubmed
  • 25) Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: signincance or stem cell source and oxygen requirement. Biol Blood Marrow Transplant. 2013;19(4):589-96.
  • 26) Crawford SW, Bowden RA, Hackman RC, et al. Gleaves CA, Meyers JD, Clark JG. Rapid dctection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med. 1988;108(2):180-5.
    pubmed
  • 27) Hakim A, Cookc KR, Pavletic SZ, et al. Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transplant. 2019;54(3):383-392.
  • 28) MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood.2017;129(1):13-21.
    pubmed
  • 29) Bergeron A, Cheng GS. Bronchiolitis Obhterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Chest Med. 2017;38(4):607-21.
    pubmed
  • 30) Williams KM, Cheng GS, Pusic I, et al. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016;22(4):710-6.
    pubmed
  • 31) Bergeron A, Chevret S, Chagnon K, et al. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015;191(11):1242-9.
    pubmed
  • 32) Lucid CE, Savani BN, Engelhardt BG, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant. 2011;46(3):426-9.
    pubmed
  • 33) Hefazi M, Langer KJ, Khera N et al. Extracorporeal Photopheresis improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. Biol Blood Marrow Transplant. 2018;24(9):1906-13.
    pubmed
  • 34) Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40(3):273-7.
    pubmed
  • 35) Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for stcroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter. phase II study. Haematologica. 2010;95(11):1935-42.
    pubmed
  • 36) Yanik GA, Mineishi S, Levine JE, et al. Soluble tumor necrosis factor receptor: enbrel(etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(7):1044-54
  • 37) Tran J, Norder EE, Diaz PT, et al. Pulmonary rehabilitation for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(8):1250-4.
    pubmed
  • 38) Chen F, Yamane M, Inoue M, et al. Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor. Am J Transplant. 2011;11(7):1509-16.
    pubmed
  • 39) Sugimoto S, Miyoshi K, Kurosaki T, et al. Favorable survival in lung transplant recipients on preopcrative low-dose, as compared to high-dose corticosteroids, after hematopoietic stem cell transplantation. Int J Hematol. 2018;107(6):696-702.
    pubmed
  • 40) Holm AM, Riise GC, Hansson L, et al. Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT. Bone Marrow Transplant. 2013;48(5):703-7.
    pubmed
  • 41) Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51(6):778-85.
はじめての方へ
個人／法人会員登録のご案内